GeneDx Reports 41% Revenue Growth in 2025, Sets 33–35% Growth Guidance for 2026
GeneDx reported preliminary 2025 revenues of approximately $427 million, up 41% year-over-year, with fourth-quarter revenue of $121 million growing 27% and exome and genome revenues rising 54%. For full-year 2026, management forecasts revenues of $540–555 million, exome and genome growth of 33–35%, and at least 70% gross margin.
1. GeneDx Shares Fall on Conservative 2026 Outlook
On Monday, GeneDx stock plunged 14% after management unveiled full-year 2026 revenue guidance of $540 million to $555 million, representing 27% to 30% growth versus expectations for high-growth biotech names. Investors had anticipated an acceleration beyond the company’s estimated 33% to 35% expansion in exome and genome revenues, and the tempered top-line forecast erased gains built up over the past two weeks, signaling renewed concerns over the sustainability of breakneck growth rates.
2. Preliminary 2025 Results Highlight Robust Momentum
GeneDx reported preliminary full-year 2025 revenues of approximately $427 million, up 41% year-over-year, driven by a 54% increase in exome and genome revenues to $360 million. Volume growth reached 30.5%, with 97,271 test results delivered during the period. Fourth-quarter revenues rose 27% to $121 million, supported by accessioning more than 30,000 patients, and the company achieved a GAAP gross margin near 70%, underscoring operational leverage in its AI-driven platform and rare-disease dataset.
3. Guidance Sparks Debate on Long-Term Scalability
While management emphasized a strategic focus on durable, profitable growth—targeting adjusted gross margins of at least 70% and positive net income in 2026—analysts questioned whether the planned reinvestment in international expansion, commercial scale-up and R&D around the GeneDx Infinity dataset could compress margins or delay near-term earnings leverage. The guidance also assumes acceleration in exome/genome volume growth to 33–35%, a rate that investors worry may prove challenging given reimbursement headwinds and intensifying competition.
4. Komodo Health Partnership to Enhance Data Monetization
In a bid to diversify revenue streams, GeneDx announced a collaboration with Komodo Health to integrate genomic data with real-world clinical and claims insights. The alliance will enable new licensing agreements with biopharma clients seeking endpoint-linked datasets for rare-disease research. By combining nearly one million exomes and genomes with longitudinal patient journeys across Komodo’s database, management expects to unlock multi-million-dollar contracts over the next 12 to 18 months, reinforcing GeneDx’s position as a leading genomic insights provider.